In recent years, advances in targeted therapies, including Bruton's tyrosine kinase inhibitors (BTKis), BCL‐2 inhibitors, and chimeric antigen receptor (CAR) T cell therapy, have significantly improved outcomes in relapsed/refractory (R/R) MCL. This evidence concerns the gene BTK and mantle cell lymphoma.